Ilomastat

Summary

Ilomastat (also known as galardin or GM‑6001) is a research‑grade, broad‑spectrum matrix metalloproteinase (MMP) inhibitor belonging to the hydroxamic‑acid peptidomimetic class. It is investigated for anti‑inflammatory, antifibrotic, radioprotective and anti‑cancer applications in pre‑clinical models, and has been formulated for topical ocular delivery. The compound is not approved for any therapeutic indication and is used experimentally via intravenous, subcutaneous or topical routes.

Mechanism of Action

Ilomastat contains a hydroxamic acid moiety that chelates the catalytic zinc ion in the active site of MMPs, thereby blocking substrate hydrolysis. This inhibition is broad, affecting several MMP family members including gelatinases (MMP‑2, MMP‑9) and other collagenases. By preventing extracellular‑matrix degradation, ilomastat reduces tissue remodeling, inflammatory cell migration and fibrosis that are driven by excessive MMP activity.

What the Research Shows

Pre‑clinical studies have shown that ilomastat (or related batimastat derivatives) reduces neutrophil‑derived MMP‑9 release and prevents cavitation in rat models of lacunar infarction. In sulfur‑mustard lung injury models, protease inhibition with ilomastat is listed among strategies that mitigate epithelial barrier disruption. An eye‑drop formulation using cyclodextrin increased ilomastat solubility, penetrated rabbit ocular tissues, and inhibited fibroblast‑mediated collagen contraction, suggesting antifibrotic potential in glaucoma surgery. In mice exposed to whole‑body irradiation, pretreatment lowered TGF‑β1 and TNF‑α, preserved bone‑marrow progenitor cells, and improved survival. Bioinformatic analyses of ulcerative colitis‑associated colorectal cancer identified ilomastat as a high‑affinity MMP‑1 inhibitor, proposing a role in inflammation‑driven cancer therapy. Across these studies, evidence remains confined to animal or in‑silico work.

Reported Benefits

Animal data indicate that ilomastat can blunt MMP‑9‑driven tissue damage in brain and lung injury, reduce inflammatory cytokine surges after radiation, and preserve hematopoietic stem and progenitor cells, enhancing survival. Topical ocular delivery achieved therapeutic concentrations in sclera and aqueous humor, maintaining antifibrotic activity in vitro. Computational docking suggests strong binding to MMP‑1, supporting a hypothesis of anti‑cancer activity in inflammation‑associated colorectal cancer. Collectively, the compound shows promise as an anti‑inflammatory, antifibrotic and radioprotective agent in pre‑clinical settings.

Limitations of the Evidence

All reported effects derive from rodent models, cell cultures or computational predictions; no human clinical trials have evaluated ilomastat for these indications. Selectivity for individual MMPs remains limited, a factor implicated in the disappointing outcomes of earlier MMP inhibitor cancer trials. The ocular study examined only pharmacokinetics and in‑vitro activity, not clinical efficacy. Bioinformatic identification of ilomastat as a therapeutic candidate lacks experimental validation. Consequently, translational relevance and optimal dosing remain unknown.

Safety Considerations

The abstracts do not provide human safety data for ilomastat. Earlier clinical cancer trials with related MMP inhibitors reported dose‑limiting musculoskeletal pain and inflammation, suggesting potential class‑related adverse effects. Pre‑clinical studies referenced did not report overt toxicity, but animal tolerability does not guarantee human safety. Until formal toxicology and clinical assessments are performed, caution is warranted regarding off‑target effects and possible musculoskeletal or inflammatory reactions.

How It Is Administered

Ilomastat has been administered intravenously and subcutaneously in experimental settings. A topical ocular formulation (ilomastat‑cyclodextrin eye drops) has been developed for local delivery to the conjunctiva, sclera and aqueous humor. Formulation strategies aim to improve aqueous solubility and tissue penetration; other routes have not been systematically evaluated in humans.

Routes of Administration

Goals & Uses

• Anti-angiogenesisOncology / VascularLow
• Corneal wound healing / persistent epithelial defectsOphthalmologyModerate
• Inflammatory disease suppressionInflammationLow
• Anti-tumor / cancer invasion suppressionOncologyLow
• Research tool: MMP pathway dissectionResearchHigh

Contraindications

• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Known hypersensitivity to hydroxamic acid derivativesAllergyHigh

Adverse Effects

• Musculoskeletal syndrome (MSS)MusculoskeletalCommon
• Nausea / GI disturbanceGastrointestinalUncommon
• Local ocular irritationOphthalmicUncommon

Drug Interactions

• Anticoagulants (e.g., warfarin)Low
• Other MMP inhibitors / metalloprotease inhibitorsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Lactating womenReproductiveRelative
• Patients with hepatic or renal impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionInvestigationalNo EMA marketing authorization; used in research and limited investigational studies.
• United StatesInvestigationalStudied in Phase II clinical trials for corneal epithelial defects (topical formulation); not FDA-approved. Widely available as a research reagent.
• United KingdomInvestigationalNo MHRA approval; research use only.

Not approved by FDA, EMA, or MHRA for systemic clinical use. Has been evaluated in clinical trials for corneal epithelial defects (topical ophthalmic). Primarily used as a laboratory research reagent. Previous broader MMP inhibitor drug class faced setbacks in oncology trials due to musculoskeletal toxicity.

Evidence & Sources

• Neutrophil Infiltration and Matrix Metalloproteinase-9 in Lacunar Infarction
  Journal ArticleModerateWalz W, Cayabyab FS2017-01-01T00:00:00.000000Z
• Sulfur mustard-induced pulmonary injury: therapeutic approaches to mitigating toxicity
  Journal ArticleModerateWeinberger B, et al.2011-01-01T00:00:00.000000Z
• A novel strategy for designing specific gelatinase A inhibitors: potential use to control tumor progression
  Journal ArticleModerateAugé F, Hornebeck W, Laronze JY2004-01-01T00:00:00.000000Z
• An Ilomastat-CD Eye Drop Formulation to Treat Ocular Scarring
  Journal ArticleLowMohamed-Ahmed AHA, et al.2017-01-01T00:00:00.000000Z
• Ilomastat contributes to the survival of mouse after irradiation via promoting the recovery of hematopoietic system
  Journal ArticleLowZhao B, et al.2021-01-01T00:00:00.000000Z
• Integrated multidimensional bioinformatics analysis of the molecular mechanisms of ulcerative colitis-associated colorectal cancer and MMP1 as a potential therapeutic target
  Journal ArticleLowYu X, et al.2025-01-01T00:00:00.000000Z

Frequently Asked Questions